NCT06988059招募中1 期
A Clinical Study to Explore the Safety, Efficacy, and Pharmacokinetics of CT0596 CAR-T Cell Injection in Patients With Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2025年6月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- MTD and/or dose range
研究概览
简要总结
This study is a single-arm, open-label, exploratory dose-escalation and dosefinding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with PCL.
详细描述
This study is a single-arm, open-label, exploratory dose-escalation and dosefinding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with PCL. During the trial, dose increases or decreases or dose expansion may be performed using i3+3 principle based on the safety and ,tolerability and PK data of the patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must voluntarily sign the informed consent form (ICF) and must be willing and be able to adhere to the trial visit schedule and other protocol requirements and agree to be in long term follow-up (LTFU) for up to 15 years as mandated by the regulatory guidelines.
- •Age ≥ 18 years;
- •PCL after inductive treatment or R/R pPCL.
- •Patients must have measurable disease。
- •Expected survival > 12 weeks;
- •Eastern Cooperative Oncology Group (ECOG) score 0- 1 ;
- •Patients should have good organ function。
- •Female patients of childbearing potential must have a negative pregnancy test at screening and prior to receiving lymphodepletion therapy and are willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment and are absolutely prohibited from donating eggs for 1 year after receiving study treatment infusion during the study ;Male patients are willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment if they are sexually active with a female of childbearing potential. Sperm donation is absolutely prohibited within 1 year following study treatment infusion for all male patients during the study.
排除标准
- •Pregnant or lactating women;
- •Patients seropositive for HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infection. History of treated hepatitis B or C is permitted if the viral load is undetectable per qPCR and or nucleic acid testing;
- •Patients with any uncontrolled active infection, including but not limited to patients with active tuberculosis (investigator 's judgment);
- •Toxicities caused by previous treatment have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) ≤ Grade 1, except alopecia and other events that are judged tolerable by the investigator;
- •Patient has any significant condition(s), laboratory abnormality or psychiatric illness that would impair the ability of the patient to receive or tolerate the planned treatment or in the opinion of the investigator, participation would not be in the best interest of the patient (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- •Previous allogeneic stem cell transplantation; autologous stem cell transplantation within 12 weeks prior to signing informed consent;
- •Have received treatment for the disease within 14 days or five half-lives before preconditioning
- •Have received cell therapy within 28 days before informed consent.
- •Systemic glucocorticoids equivalent to > 15 mg/day prednisone within 7 days prior to informed consent, with the exception of topical glucocorticoids;
- •Vaccination with live attenuated vaccines , inactivated vaccines or RNA vaccines within 4 weeks prior to informed consent;
- •Major surgery within 2 weeks before informed consent or planned during the study period or within 4 weeks after giving study treatment (excluding local anesthesia such as cataract);
- •Allergic or intolerant to lymphodepletion, tocilizumab, or allergic to components (DMSO) in CT0596 CART cell infusion preparation; or previous history of other serious allergies such as anaphylactic shock;
- •Patients with secondary plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome, or primary light chain amyloidosis at screening;
- •Patients with any of the following cardiac conditions within 6 months prior to screening:
- •Patients who require supplemental oxygen to maintain oxygen saturation > 92%; or Patients with known or suspected COPD who have Forced Expiratory Volume in 1 second (FEV1) < 50% of predicted normal on spirometry;
- •Patients with active autoimmune diseases, including but not limited to psoriasis, rheumatoid arthritis and other diseases requiring long-term immunosuppressive therapy;
- •Patients with second primary malignancies in addition to MM are not eligible if the second primary malignancy has required treatment within the past 2 years or is not in complete remission. Exceptions include the following that have been successfully treated - nonmetastatic basal cell or squamous cell skin carcinoma, non-metastatic prostate cancer, carcinoma-in-situ of breast or cervix, non-muscle invasive bladder cancer
- •Patients with symptomatic central nervous system (CNS) disease or suspected CNS metastases;
- •The patient is unable or unwilling to comply with protocol, or there are other reasons for being unsuitable to participate in this clinical study evaluated by investigators.
研究组 & 干预措施
CAR-T cells Infusion chimeric antigen receptor T cells
Experimental
干预措施: CAR-T cells Infusion chimeric antigen receptor T cells (Drug)
结局指标
主要结局
MTD and/or dose range
时间窗: 12 months after CT0596 infusion
Evaluate Dose limited toxicity and recommended dosage range after CT0596 infusion
Adverse Events (AE) after CT0596 infusion
时间窗: 12 months after CT0596 infusion
An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria
次要结局
- Overall response rate (ORR) as assessed by the investigator(12 months after CT0596 infusion)
- Complete response/stringent complete response (CR/sCR) rate(12 months after CT0596 infusion)
- Rate of very good partial response (VGPR) and above(12 months after CT0596 infusion)
- Duration of response (DOR)(12 months after CT0596 infusion)
- Minimal residual disease (MRD) negative rate(12 months after CT0596 infusion)
- Time to response (TTR)(12 months after CT0596 infusion)
- Progression-free survival (PFS)(12 months after CT0596 infusion)
- Peak value of CART cells(12 months after CT0596 infusion)
- Overall survival (OS)(12 months after CT0596 infusion)
- Cytokines in the peripheral blood after CT0596 infusion(12 months after CT0596 infusion)
- Area under the plasma concentration versus time curve (AUC) of CART cells(12 months after CT0596 infusion)
- In vivo persistence of CART cells(12 months after CT0596 infusion])
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell LeukemiaNCT06718270Shanghai Changzheng Hospital24
招募中
早期 1 期
Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2NCT06920199Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine18
进行中（未招募）
1 期
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid TumorsColorectalPancreaticNon-small Cell Lung Cancer (NSCLC)NCT06767046Corregene Biotechnology Co., Ltd8
招募中
1 期
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT06880354Institute of Hematology & Blood Diseases Hospital, China37
终止
1 期
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaNCT05376345Shanghai Changzheng Hospital24